A Phase 1/2 interventional study of NDV-3A and NDV-3 in Vulvovaginal Candidiasis, sponsored by NovaDigm Therapeutics, Inc.. Completed at 20 sites in United States. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2018-07-18.
Sponsored by NovaDigm Therapeutics, Inc. · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Candidiasis, Vulvovaginal with a site in United States — 3 open to participants now, 4 under way, none of them phase 3. Candidiasis, Vulvovaginal · United States.
Among the 33 studies in Candidiasis, Vulvovaginal with a site in United States, this one is the 14th largest by enrollment of the 28 interventional ones that give a count, is one of 4 that started in 2013, is the only one in phase 1/2, and was the 9th registered.
109 studies on the registry are indexed under Candidiasis, Vulvovaginal; 14 are open to participants now.
Browse Candidiasis, Vulvovaginal studies →3 of the 33 studies in Candidiasis, Vulvovaginal with a site in United States are open now. Recruiting first, the newest first:
Sano Chemicals Inc · Sites in United States
Ages 18–65 · Women only
Coologics, Inc · Sites in United States
Ages 22–49 · Women only
Queen's Medical Center · Sites in United States
Ages 18–54 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 11 Candidiasis, Vulvovaginal studies recruiting now, 4 (36%) set no upper age limit and 7 (64%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 50 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 11 · Phase 3 9 · Phase 4 1
First in 2004; this study’s year is marked. 4 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 188 is above the median of 126 across 91 interventional studies indexed under Candidiasis, Vulvovaginal.
Median enrollment 187 across the 28 interventional studies, 300 across the 5 observational. Of the 28 that completed or were terminated, 17 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 33 have an industry lead sponsor. The 10 most frequent:
NovaDigm Therapeutics, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.
NovaDigm Therapeutics, Inc. has 1 study filed under Candidiasis, Vulvovaginal — fewer than ten, so there is no comparison to draw.
2 of the studies in Candidiasis, Vulvovaginal with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07521137Sano Chemicals IncBiweekly Long-term Occidiofungin Study for Suppression of Mycotic Recurrence | 2026-12-31 |
| NCT05079711Uniformed Services University of the Health SciencesComparative Performance of a Vaginal Yeast Test | 2027-10-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 33 studies in Candidiasis, Vulvovaginal with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multi-center, randomized, double-blind, placebo-controlled study intended to assess the safety, tolerability and humoral and cellular immune response over a 12-month period after receiving one dose of either the NDV-3A vaccine, NDV-3 vaccine, or placebo. In addition, the clinical efficacy of NDV-3A vaccine in lowering the recurrence rate of vulvovaginal candidiasis (VVC) in patients with recurrent VVC (RVVC) will be evaluated relative to placebo.
The purpose of the Phase 1b portion of this study is to compare the NDV-3A vaccine, the NDV-3 vaccine and the placebo head-to-head in the patient population of interest (women with RVVC) to evaluate safety and immunogenicity. The study size for comparing safety and immunogenicity (N=15 per group) is based on the dose comparison design used in study NDV3-001 (clinical trials.gov Identifier NCT01273922).
The primary purpose of the Phase 2a portion of this study is to further evaluate safety, tolerability, and immunogenicity of the NDV-3A vaccine compared to placebo in a patient population of interest (women with RVVC). The secondary purpose is to determine whether the NDV-3A vaccine decreases the recurrence rate of VVC in 18-50 year old women with RVVC when compared to placebo. The study size for evaluating efficacy (N=87 per group) is based on assuming a 50% rate of VVC recurrences over the 6 month post-vaccination period in the placebo group and a 50% vaccine efficacy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Experimental Vaccine: a purified, recombinant antigen (rAls3) formulated with aluminum hydroxide adjuvant
Biological: NDV-3A
Experimental Vaccine: a purified, recombinant antigen (rAls3 with 6-His tag) formulated with aluminum hydroxide adjuvant
Biological: NDV-3
Placebo: aluminum hydroxide adjuvant
Biological: Placebo
0.5mL injection IM
0.5mL injection IM
aluminum hydroxide and buffered saline
Summary of Injection Site Reactions for the Safety Population Over the 12-months Post Vaccination Period
Summary of injection site reactions for the safety population over the 12-months post-vaccination period in the NDV-3A vaccine group, the NDV-3 vaccine group, and the placebo group.
Time frame: 12-month
Number of Patients <40 Years Old Who Were Recurrence-free Over the 12-month Post-vaccination Period
Number of patients \<40 years old with documented RVVC who were recurrence-free over the 12-month post-vaccination period in the NDV-3A vaccine group and the placebo group
Time frame: 12 months
Number of Patients Who Were Recurrence-free Over the 12-month Post-vaccination Period
Number of patients with documented RVVC who were recurrence-free over the 12-month post-vaccination period in the NDV-3A vaccine group and the placebo group
Time frame: 12 months
Time to First VVC Episode From Study Day 17 to 360 - Participants <40 Years Old
Time-to-onset of first VVC episode from Study Day 17 for the NDV-3A vaccine group and the placebo group
Time frame: 12 months
Time to First VVC Episode From Study Day 17 to 360 - All Participants
Time-to-onset of first VVC episode from Study Day 17 for the NDV-3A vaccine group and the placebo group
Time frame: 12 months
Serum Anti-Als3 IgG Titers Over the 12-month Post-vaccination Period
Serum anti-Als3 IgG titers will be measured by ELISA at pre-defined time points over the 12-month post-vaccination period in the NDV-3A vaccine group, the NDV-3 vaccine group, and the placebo group.
Time frame: 0, 14, 28, 90, 180 and 360 days
Serum Anti-Als3 IgA1 Titers Over the 12-month Post-vaccination Period
Serum anti-Als3 IgA1 titers will be measured by ELISA at pre-defined time points over the 12-month post-vaccination period in the NDV-3A vaccine group, the NDV-3 vaccine group, and the placebo group.
Time frame: 0, 14, 28, 90, 180 and 360 days
Cervicovaginal Wash Anti-Als3 IgG Titers Over the 12-month Post-vaccination Period
Cervicovaginal wash anti-Als3 IgG titers will be measured by ELISA at pre-defined time points over the 12-month post-vaccination period in the NDV-3A vaccine group, the NDV-3 vaccine group, and the placebo group.
Time frame: 0, 14, 28, 90, 180 and 360 days
Cervicovaginal Wash Anti-Als3 IgA1 Titers Over the 12-month Post-vaccination Period
Cervicovaginal wash anti-Als3 IgA1 titers will be measured by ELISA at pre-defined time points over the 12-month post-vaccination period in the NDV-3A vaccine group, the NDV-3 vaccine group, and the placebo group.
Time frame: 0, 14, 28, 90, 180 and 360 days
Als3-specific T-cell Production of Interferon Gamma Over the Post-vaccination Period
Als3-specific T-cell production of interferon gamma will be measured by enzyme-linked immunospot (ELISpot) at pre-defined time points over the 12-month post-vaccination period in the NDV-3A vaccine group, the NDV-3 vaccine group, and the placebo group.
Time frame: 0, 14, 90 days
Als3-specific T-cell Production of Interleukin-17A Over the Post-vaccination Period
Als3-specific T-cell production of interleukin-17A will be measured by enzyme-linked immunospot (ELISpot) at pre-defined time points over the 12-month post-vaccination period in the NDV-3A vaccine group, the NDV-3 vaccine group, and the placebo group.
Time frame: 0, 14, 90 days
| Milestone | Placebo | NDV-3A | NDV-3 |
|---|---|---|---|
| Started | 85 | 89 | 14 |
| Completed | 64 | 67 | 12 |
| Not completed | 21 | 22 | 2 |
| Withdrew: Lost to follow-up | 7 | 6 | 0 |
| Withdrew: Physician decision | 1 | 5 | 0 |
| Withdrew: Withdrawal by subject | 9 | 9 | 2 |
| Withdrew: Non compliance or other reasons | 4 | 2 | 0 |
Summary of injection site reactions for the safety population over the 12-months post-vaccination period in the NDV-3A vaccine group, the NDV-3 vaccine group, and the placebo group.
| AEs | Placebo | NDV-3A | NDV-3 |
|---|---|---|---|
| Patients with >= 1 injection site reaction | 72 | 79 | 10 |
| Induration | 25 | 46 | 0 |
| Pain | 56 | 70 | 7 |
| Redness | 34 | 45 | 2 |
| Swelling | 28 | 47 | 2 |
| Tenderness | 64 | 71 | 10 |
Number of patients \<40 years old with documented RVVC who were recurrence-free over the 12-month post-vaccination period in the NDV-3A vaccine group and the placebo group
| Participants | Placebo | NDV-3A |
|---|---|---|
| Number of Patients <40 Years Old Who Were Recurrence-free Over the 12-month Post-vaccination Period | 11 | 24 |
Number of patients with documented RVVC who were recurrence-free over the 12-month post-vaccination period in the NDV-3A vaccine group and the placebo group
| Participants | Placebo | NDV-3A |
|---|---|---|
| Number of Patients Who Were Recurrence-free Over the 12-month Post-vaccination Period | 17 | 28 |
Time-to-onset of first VVC episode from Study Day 17 for the NDV-3A vaccine group and the placebo group
| Days | Placebo | NDV-3A |
|---|---|---|
| Time to First VVC Episode From Study Day 17 to 360 - Participants <40 Years Old | 105 (45 to 325) | 210 (95 to 360) |
Time-to-onset of first VVC episode from Study Day 17 for the NDV-3A vaccine group and the placebo group
| Days | Placebo | NDV-3A |
|---|---|---|
| Time to First VVC Episode From Study Day 17 to 360 - All Participants | 135 (50 to 330) | 175 (70 to 350) |
Serum anti-Als3 IgG titers will be measured by ELISA at pre-defined time points over the 12-month post-vaccination period in the NDV-3A vaccine group, the NDV-3 vaccine group, and the placebo group.
| Titer (dilution^-1) | Placebo | NDV-3A | NDV-3 |
|---|---|---|---|
| Day 0 | 465 ± 3.3 | 434 ± 3.5 | 305 ± 3.1 |
| Day 14 | 464 ± 3.6 | 37381 ± 3.9 | 18078 ± 4.6 |
| Day 28 | 419 ± 3.3 | 31459 ± 3.6 | 13674 ± 4.6 |
| Day 90 | 447 ± 3.2 | 17818 ± 3.5 | 10868 ± 3.8 |
| Day 180 | 523 ± 3.5 | 10852 ± 3.5 | 6297 ± 3.9 |
| Day 360 | 371 ± 3.6 | 5349 ± 3.2 | 4999 ± 3.9 |
Serum anti-Als3 IgA1 titers will be measured by ELISA at pre-defined time points over the 12-month post-vaccination period in the NDV-3A vaccine group, the NDV-3 vaccine group, and the placebo group.
| Titer (dilution^-1) | Placebo | NDV-3A | NDV-3 |
|---|---|---|---|
| Day 0 | 937 ± 5.6 | 1011 ± 5.5 | 657 ± 3.1 |
| Day 14 | 954 ± 6.4 | 63834 ± 5.1 | 44866 ± 3.7 |
| Day 28 | 850 ± 5.5 | 43557 ± 5.2 | 30118 ± 3.2 |
| Day 90 | 1062 ± 6.0 | 23053 ± 5.1 | 20349 ± 3.1 |
| Day 180 | 982 ± 7.3 | 18215 ± 5.9 | 14633 ± 3.4 |
| Day 360 | 563 ± 7.3 | 8727 ± 5.8 | 12357 ± 3.1 |
Cervicovaginal wash anti-Als3 IgG titers will be measured by ELISA at pre-defined time points over the 12-month post-vaccination period in the NDV-3A vaccine group, the NDV-3 vaccine group, and the placebo group.
| Titer (dilution^-1) | Placebo | NDV-3A | NDV-3 |
|---|---|---|---|
| Day 0 | 2.03 ± 5.27 | 1.93 ± 4.19 | 1.47 ± 4.69 |
| Day 14 | 1.93 ± 5.15 | 20.67 ± 6.28 | 8.01 ± 8.09 |
| Day 28 | 1.44 ± 3.63 | 24.98 ± 6.97 | 9.88 ± 14.49 |
| Day 90 | 1.40 ± 3.97 | 14.28 ± 6.16 | 5.28 ± 4.11 |
| Day 180 | 1.66 ± 4.55 | 7.68 ± 6.73 | 2.72 ± 6.42 |
| Day 360 | 1.44 ± 5.14 | 4.36 ± 6.39 | 2.76 ± 6.12 |
Cervicovaginal wash anti-Als3 IgA1 titers will be measured by ELISA at pre-defined time points over the 12-month post-vaccination period in the NDV-3A vaccine group, the NDV-3 vaccine group, and the placebo group.
| Titer (dilution^-1) | Placebo | NDV-3A | NDV-3 |
|---|---|---|---|
| Day 0 | 4.86 ± 6.37 | 5.16 ± 5.38 | 2.02 ± 6.81 |
| Day 14 | 4.99 ± 7.89 | 53.65 ± 7.00 | 28.24 ± 6.86 |
| Day 28 | 3.44 ± 4.51 | 45.96 ± 8.56 | 22.22 ± 9.61 |
| Day 90 | 2.87 ± 4.89 | 22.52 ± 7.50 | 5.75 ± 6.00 |
| Day 180 | 3.13 ± 5.60 | 17.74 ± 5.76 | 10.17 ± 4.83 |
| Day 360 | 3.39 ± 5.05 | 9.32 ± 7.06 | 5.02 ± 7.41 |
Als3-specific T-cell production of interferon gamma will be measured by enzyme-linked immunospot (ELISpot) at pre-defined time points over the 12-month post-vaccination period in the NDV-3A vaccine group, the NDV-3 vaccine group, and the placebo group.
| Spot Forming Units | Placebo | NDV-3A | NDV-3 |
|---|---|---|---|
| Day 0 | 2.7 ± 3.0 | 3.6 ± 3.3 | 2.6 ± 3.4 |
| Day 14 | 3.0 ± 3.2 | 22.8 ± 5.3 | 22.1 ± 7.7 |
| Day 90 | 3.2 ± 3.5 | 16.6 ± 4.6 | 15.1 ± 4.9 |
Als3-specific T-cell production of interleukin-17A will be measured by enzyme-linked immunospot (ELISpot) at pre-defined time points over the 12-month post-vaccination period in the NDV-3A vaccine group, the NDV-3 vaccine group, and the placebo group.
| Spot Forming Units | Placebo | NDV-3A | NDV-3 |
|---|---|---|---|
| Day 0 | 3.4 ± 4.1 | 4.2 ± 4.4 | 5.2 ± 4.1 |
| Day 14 | 2.6 ± 3.4 | 9.6 ± 5.3 | 11.1 ± 5.4 |
| Day 90 | 2.9 ± 3.5 | 6.6 ± 3.9 | 3.3 ± 3.7 |
Collected over 12-months. Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/85 (0%) | 0/85 (0%) | 48/85 (56.5%) |
| NDV-3A | 0/89 (0%) | 0/89 (0%) | 35/89 (39.3%) |
| NDV-3 | 0/14 (0%) | 0/14 (0%) | 3/14 (21.4%) |
| Event | Placebo | NDV-3A | NDV-3 |
|---|---|---|---|
| Urinary tract infectionInfections and infestations | 16/85 | 7/89 | 1/14 |
| Vaginitis bacterialInfections and infestations | 15/85 | 13/89 | 1/14 |
| NasopharyngitisInfections and infestations | 6/85 | 6/89 | 1/14 |
| HeadacheNervous system disorders | 4/85 | 5/89 | 0/14 |
| AnemiaBlood and lymphatic system disorders | 4/85 | 0/89 | 0/14 |
| Upper respiratory tract infectionInfections and infestations | 3/85 | 4/89 | 0/14 |
| Age, Continuous(years) | Placebo | NDV-3A | NDV-3 | Total |
|---|---|---|---|---|
| Mean | 32.4 ± 8.80 | 32.1 ± 8.82 | 35.4 ± 10.70 | 32.5 ± 8.95 |
| Sex: Female, Male(Participants) | Placebo | NDV-3A | NDV-3 | Total |
|---|---|---|---|---|
| Female | 85 | 89 | 14 | 188 |
| Male | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | NDV-3A | NDV-3 | Total |
|---|---|---|---|---|
| Hispanic or Latino | 27 | 36 | 3 | 66 |
| Not Hispanic or Latino | 58 | 53 | 11 | 122 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | NDV-3A | NDV-3 | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 2 | 0 | 0 | 2 |
| Black or African American | 17 | 19 | 2 | 38 |
| White | 64 | 68 | 12 | 144 |
| More than one race | 1 | 1 | 0 | 2 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 |
| Region of Enrollment(Participants) | Placebo | NDV-3A | NDV-3 | Total |
|---|---|---|---|---|
| United States | 85 | 89 | 14 | 188 |
Plan to share: Yes — Presentations at scientific meetings and publication
The record gives a start of Jul 2013, a primary completion of May 2015 and a completion of May 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2018, 3 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
NovaDigm Therapeutics, Inc.